Evofem Biosciences Inc.
| NASDAQ: EVFM | Healthcare / Biotechnology / USA |
| 0.0756 | +0.0056 | +8.00% | Vol 101.70K | 1Y Perf 20.48% |
| Dec 1st, 2023 15:57 DELAYED |
| BID | 0.00 | ASK | 0.00 | ||
| Open | 0.0700 | Previous Close | 0.0700 | ||
| Pre-Market | - | After-Market | - | ||
| - - | - -% |
| Target Price | 2.68 | Analyst Rating | — 0.00 | |
| Potential % | 3.44K | Finscreener Ranking | — - | |
| Insiders Trans % 3/6/12 mo. | 100/100/100 | Value Ranking | ☆ 33.11 | |
| Insiders Value % 3/6/12 mo. | 100/100/100 | Growth Ranking | — - | |
| Insiders Shares Cnt. % 3/6/12 mo. | 100/100/100 | Income Ranking | — - | |
| Price Range Ratio 52W % | 0.19 | Earnings Rating | Neutral | |
| Market Cap | 811.20K | Earnings Date | 11th Aug 2023 | |
| Alpha | -0.08 | Standard Deviation | 0.41 | |
| Beta | -1.23 |
Today's Price Range 0.06400.0756 | 52W Range 0.055010.63 | 5 Year PE Ratio Range -0.9000-0.2000 |
Summary:
Neutral
| Technical Indicators: | Neutral |
| Moving Averages: | Sell |
| Performance | |||
|---|---|---|---|
| 1 Week | 8.53% | ||
| 1 Month | -3.45% | ||
| 3 Months | -63.16% | ||
| 6 Months | 354.55% | ||
| 1 Year | 20.48% | ||
| 3 Years | -96.77% | ||
| 5 Years | -98.00% | ||
| 10 Years | - |
| Mngmt Effectiveness | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
ROE (5Y Avg) | 128.78 | |||
ROE last 12 Months | 271.73 | |||
ROA (5Y Avg) | -133.13 | |||
ROA last 12 Months | -378.02 | |||
ROC (5Y Avg) | - | |||
ROC last 12 Months | -146.30 | |||
Return on invested Capital Q | -44.21 | |||
Return on invested Capital Y | -30 623.60 | |||
Assets Turnover | 0.20 | |||
Receivables Turnover | 1.60 |
| Valuation | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| 0.00 | ||||
| 8.37 | ||||
| 0.72 | ||||
| - | ||||
| -0.10 | ||||
| -7.15 | ||||
| -0.03 | ||||
| -2.53 | ||||
| 111.75M | ||||
| Forward PE | -0.08 | |||
| PEG | - |
| Financial Strength | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| 0.10 | ||||
| 0.20 | ||||
| 0.78 | ||||
| 8.72 | ||||
| - | ||||
| Leverage Ratio | -0.30 |
| Profitability | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| 67.50 | ||||
| -861.70 | ||||
| -854.80 | ||||
| - | ||||
| - |
| Revenue | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| 10.29M | ||||
| 0.08 | ||||
| - | ||||
| - |
| Dividends | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| - | ||||
| - | ||||
| - | ||||
| - | ||||
| Payout ratio | - |
| Earnings History | Estimate | Reported | Surprise % |
|---|---|---|---|
| Q02 2023 | - | -5.43 | - |
| Q01 2023 | - | -1.85 | - |
| Q02 2022 | -126.25 | -571.25 | -352.48 |
| Q01 2022 | -373.75 | -360.00 | 3.68 |
| Q04 2021 | -431.04 | -618.44 | -43.48 |
| Q03 2021 | -4.50 | -4.35 | 3.33 |
| Q02 2021 | -5.25 | -4.05 | 22.86 |
| Q01 2021 | -7.35 | -8.40 | -14.29 |
| Earnings Per End | Estimate | Revision % | Trend |
|---|---|---|---|
| 12/2022 QR | 0.27 | 350.00 | Positive |
| 12/2022 FY | -2.69 | -16.45 | Negative |
| 3/2023 QR | -0.12 | 0.00 | - |
| 12/2023 FY | -0.72 | -28.57 | Negative |
| Next Report Date | - |
| Estimated EPS Next Report | - |
| Estimates Count | - |
| EPS Growth Next 5 Years % | - |
| Volume Overview | |
|---|---|
| Volume | 101.70K |
| Shares Outstanding | 10.73K |
| Shares Float | 10.52M |
| Trades Count | 79 |
| Dollar Volume | 7.15K |
| Avg. Volume | 196.60K |
| Avg. Weekly Volume | 149.60K |
| Avg. Monthly Volume | 241.31K |
| Avg. Quarterly Volume | 198.89K |
Evofem Biosciences Inc. (NASDAQ: EVFM) stock closed at 0.07 per share at the end of the most recent trading day (a 4.95% change compared to the prior day closing price) with a volume of 53.36K shares and market capitalization of 811.19K. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 53 people. Evofem Biosciences Inc. CEO is Saundra Pelletier.
The one-year performance of Evofem Biosciences Inc. stock is 20.48%, while year-to-date (YTD) performance is 9.38%. EVFM stock has a five-year performance of -98%. Its 52-week range is between 0.055 and 10.625, which gives EVFM stock a 52-week price range ratio of 0.19%
Evofem Biosciences Inc. currently has a PE ratio of 0.00, a price-to-book (PB) ratio of 8.37, a price-to-sale (PS) ratio of 0.72, a price to cashflow ratio of -, a PEG ratio of -, a ROA of -378.02%, a ROC of -146.30% and a ROE of 271.73%. The company’s profit margin is -%, its EBITDA margin is -854.80%, and its revenue ttm is $10.29 Million , which makes it $0.08 revenue per share.
Of the last four earnings reports from Evofem Biosciences Inc., there were 1 positive earnings surprise and 1 negative earnings surprise. The company has EPS estimate of $0.00 for the next earnings report. Evofem Biosciences Inc.’s next earnings report date is -.
The consensus rating of Wall Street analysts for Evofem Biosciences Inc. is — (0), with a target price of $2.68, which is +3 444.97% compared to the current price. The earnings rating for Evofem Biosciences Inc. stock is Neutral (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).
Evofem Biosciences Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.
Evofem Biosciences Inc. has a Neutral technical analysis rating based on Technical Indicators (ADX : 28.04, ATR14 : 0.02, CCI20 : -28.35, Chaikin Money Flow : -0.15, MACD : -0.01, Money Flow Index : 22.74, ROC : 7.69, RSI : 43.45, STOCH (14,3) : 60.00, STOCH RSI : 1.00, UO : 35.95, Williams %R : -40.00), Simple Moving Averages and Exponential Moving Averages.
Aggregated Insider Trades of Evofem Biosciences Inc. in the last 12-months were:
Evofem Biosciences Inc.
Evofem Biosciences Inc is a commercial-stage biopharmaceutical company committed to developing and commercializing innovative products to address unmet needs in women's sexual and reproductive health. Its focus is to advance the quality of life for women by developing solutions such as hormone-free, woman-controlled contraception and protection from certain sexually transmitted infections. Its first commercial product, Phexxi (lactic acid, citric acid, and potassium bitartrate) vaginal gel, is for the prevention of pregnancy. Phexxi is hormone-free, female-controlled, on-demand prescription contraceptive gel. Its pipeline product candidate, EVO100, is being evaluated for the prevention of chlamydia and gonorrhea - two of the pervasive sexually transmitted diseases in the United States.
CEO: Saundra Pelletier
Telephone: +1 858 550-1900
Address: 12400 High Bluff Drive, San Diego 92130, CA, US
Number of employees: 53
